|A multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose ranging study to evaluate the safety, efficacy, pharmacokinetics, and pharmacodynamics of bimekizumab in adult subjects with moderate to severe chronic plaque psoriasis||The primary objective of the study is to evaluate the dose response of bimekizumab (also known as UCB4940) administered subcutaneously (sc) every 4 weeks (Q4W) for 12 weeks in the treatment of subjects with moderate to severe chronic plaque psoriasis.
|Photodynamic Therapy for Papulopustular Rosacea||Dermatology at The GW Medical Faculty Associates is conducting an experimental research study to examine the efficacy of 5-aminolevulinic acid photodynamic therapy (5-ALA PDT) in treating rosacea. The purpose of this study is to evaluate if using 5-ALA PDT improves rosacea symptoms.
We are seeking individuals with rosacea between the ages of 18 and 79 to volunteer to participate in this study. This study will take a total of six months (six total visits to the MFA). Prior to each visit, you will be examined and fill out a questionnaire. Participation in the study will be of no direct cost to you. If you are interested in participating in this research study, please contact Dermatology at
The GW Medical Faculty Associates.
|Prurigo Nodularis (Chronic Prurigo)||This study is a 12-month, observational, non-interventional study assessing biomarkers, clinical outcomes, and treatment-responsiveness in patients with prurigo nodularis (PN).Patients must be 18 years or older with a confirmed diagnosis of PN (with predominantly nodular disease) by the PI. They must be able to read and understand the consent form and outcomes questionnaires and willing and able to sign the consent form. A separate consent form will be used for genomics testing, which is encouraged for all study participants but not required. Lastly, patients must be willing to participate in the following study-related activities:
1) Completion of outcome questionnaires
2) Actigraphy data collection
3) Biomarker collection by blood draws at each monthly study visit
4) Skin biopsy collection
5) Medical photography (8-24 photos taken each visit)
|Study for patients with moderate to severe Chronic Plaque Psoriasis - A Phase 3, Randomized, double-blind and open label study to test the safety and efficacy of Certolizumab Pegol in subjects with moderate to severe Chronic Plaque Psoriasis||The study will test the safety and effectiveness of Certolizumab Pegol vs placebo in patients with Chronic Plaque Psoriasis. An Open Label study will follow the placebo phase.